Barbara Rodriguez
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,196 and has fallen 75.0% since, to $550 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$708
- GSK$443
- AstraZeneca$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$410
- Amarin Pharma, Inc.$364
- Novo Nordisk$359
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,86799%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 10 | $708 |
| GSK | 25 | $443 |
| AstraZeneca | 11 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $410 |
| Amarin Pharma, Inc. | 28 | $364 |
| Novo Nordisk | 14 | $359 |
| Eisai Inc. | 6 | $340 |
| Johnson & Johnson | 7 | $272 |
| Lilly USA, LLC | 9 | $244 |
| Boehringer Ingelheim | 4 | $190 |
| Phathom Pharmaceuticals, Inc. | 3 | $187 |
| Otsuka America Pharmaceutical, Inc. | 2 | $146 |
| UCB, Inc. | 1 | $125 |
| Neurelis, Inc. | 1 | $125 |
| AbbVie | 6 | $105 |
| Exact Sciences | 4 | $105 |
| Astellas Pharma US Inc | 3 | $100 |
| Pfizer | 4 | $93 |
| Corcept Therapeutics | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Genentech USA, Inc. | 5 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,933 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 24 | $22,161 |
| EntrestoSacubitril/Valsartan | 14 | $18,986 |
| OzempicSemaglutide | 17 | $16,397 |
| VascepaIcosapent Ethyl | 21 | $15,243 |
| JanuviaSitagliptin Phosphate | 16 | $12,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,438 |
| SavellaMilnacipran Hcl | 12 | $2,610 |
| Rosuvastatin Calcium | 94 | $1,481 |
| SynthroidLevothyroxine Sodium | 13 | $1,470 |
| Metoprolol Succinate | 75 | $1,294 |
| Losartan Potassium | 99 | $1,110 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,094 |
| Omeprazole | 65 | $1,012 |
| Testosterone Cypionate | 18 | $855 |
| Diclofenac Sodium | 60 | $834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $93 | $22,16124 claims |
| Novo NordiskOzempic | $359 | $16,39717 claims |
| GSKTrelegy Ellipta | $443 | $6,43811 claims |
| AbbVieSavella, Synthroid | $105 | $4,08025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.